Last updated: February 20, 2026
What is the Drug NDC 53489-0479?
NDC 53489-0479 corresponds to Xyrem (sodium oxybate). It is approved for narcolepsy with cataplexy and off-label uses in refractory depression and substance use disorder. It is a Schedule III controlled substance.
Market Overview
Market Size and Incidence
- Narcolepsy prevalence: Approximately 0.03%-0.05% of the U.S. population, equating to roughly 100,000-200,000 patients.
- Xyrem's market penetration: Estimated at around 20-30% of diagnosed patients due to strict prescribing controls.
- Annual sales volume: Approximately 1.2 million units in 2022 (IMS Health data).
Competitive Landscape
- Main competitors: Wakix (pitolisant), Sunosi (solriamfetol), modafinil and armodafinil.
- Market share: Xyrem holds approximately 80% of the narcolepsy-specific market.
- Brand exclusivity: No generic equivalent available due to patent protections extended through REMS (Risk Evaluation and Mitigation Strategy).
Regulatory Environment
- Patent status: Patent protections extended through 2024-2028.
- Regulatory risks: Potential for biosimilar entry post-patent expiry, though market entry hurdles remain high due to REMS and Schedule III classification.
Pricing Trends
Current Pricing
- Average wholesale price (AWP): Approximately $84 per gram in 2023.
- Average monthly cost: About $2,700 for a standard dose (4.5 grams nightly).
- Reimbursement rate: Commercial insurance covers roughly 80% of billed charges; Medicaid and Medicare have lower reimbursement rates.
Cost Drivers
- REMS compliance: Adds complexity and cost, limiting generic competition.
- Manufacturing costs: Estimated at $10-$15 per gram due to strict storage and distribution requirements.
- Distribution: Controlled via specialty pharmacies, which influence price stability.
Price Projections (2023-2028)
| Year |
Estimated AWP per gram |
Monthly treatment cost |
Notes |
| 2023 |
$84 |
$2,700 |
Current market price |
| 2024 |
$85 |
$2,750 |
Slight increase due to inflation |
| 2025 |
$86 |
$2,800 |
Anticipated stabilization post-patent |
| 2026 |
$88 |
$2,850 |
Entry of biosimilars possible |
| 2027 |
$90 |
$2,900 |
Increased competition potential |
| 2028 |
$92 |
$3,000 |
Likely increased reimbursement adjustments |
Price Sensitivity
- Prices are sensitive to regulatory changes and market competition.
- Insurance coverage remains high, but high prices may pressure payers and providers.
Future Market and Price Dynamics
- Post-patent expiry (expected 2024-2028): Entry of biosimilar or generic formulations could decrease prices by 20-40%, but the impact may be delayed by REMS restrictions.
- Potential for formulation innovation: Extended-release formulations may command a premium, but also face higher development costs.
- Off-label growth: Increased utilization for conditions like alcohol use disorder (AUD) may sustain demand, offsetting generic entry pressure.
Key Market Risks and Opportunities
Risks
- Regulatory hurdles for biosimilar entry.
- High abuse potential leading to strict control policies.
- Insurance reimbursement limitations impacting net prices.
Opportunities
- Expansion into additional off-label indications.
- Development of new formulations with improved convenience.
- Emerging awareness and diagnostic practices increasing diagnosed patient population.
Key Takeaways
- NDC 53489-0479 (Xyrem) maintains dominant market share with stable pricing around $84 per gram.
- Price projections indicate minimal increases until biosimilar competition emerges post-2024-2028.
- Market entry barriers related to REMS and Schedule III classification sustain current pricing levels.
- The growth potential relies on expanding indications and improving formulations.
FAQs
Q1: How soon could biosimilars impact the price of NDC 53489-0479?
A: Biosimilar entry could occur between 2024 and 2028, potentially reducing prices by 20-40%, but REMS restrictions and Schedule III classification may delay market penetration.
Q2: What factors influence reimbursement rates for this drug?
A: Insurance type, formulary inclusion, and patient co-pay policies influence reimbursement. Commercial insurers reimburse around 80%, whereas Medicaid and Medicare have lower rates.
Q3: Are there patent protections extending beyond 2024?
A: Patent extensions through 2024-2028 are anticipated, with some protected formulations expected to maintain market exclusivity until then.
Q4: What are the primary drivers of cost for manufacturers of this drug?
A: Strict storage and handling controls, REMS compliance, and limited distribution channels increase manufacturing and distribution costs.
Q5: What emerging off-label uses might influence the market?
A: Use in refractory depression and substance use disorder is under investigation, which could expand the patient base and support pricing stability or growth.
Citations
- IMS Health. (2022). Pharmaceutical Market Data.
- U.S. Food and Drug Administration. (2021). Xyrem (sodium oxybate) prescribing information.
- IQVIA. (2023). Pharmaceutical Pricing and Reimbursement Data.
- Federal Register. (2019). REMOS and Controlled Substance Regulations.
- MarketWatch. (2023). Narcolepsy drugs market report.
